Order byBest matchMost fresh

Hims & Hers, Zepbound

Digest more
Top News
Impacts
The Wall Street Journal |
The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.
U.S. News & World Report |
Hims & Hers expects at least $725 million in revenue from its weight-loss services alone in 2025.

Read more on News Digest

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact
Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company announced it was adding two new weight-loss medications to its platform. According to a post on the company's website by Craig Primack,
Hims & Hers to sell Lilly’s Zepbound
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.
Insurance Coverage For Ozempic, Zepbound Went Down In 2025
While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for meds like Ozempic and Zepbound has decreased.
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.
Hims & Hers adding access to generic liraglutide, branded tirzepatide
Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way we’ve built the Hims & Hers platform and is especially important in how we designed our weight loss offering,
GLP-1 drugs could become tougher to get. 3 cheap supplements that can aid weight loss
Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately.
Explore more
Feedback